Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 6, 2017
|
| In: |
Circulation
Year: 2017, Volume: 135, Issue: 10, Pages: 1001-1003 |
| ISSN: | 1524-4539 |
| DOI: | 10.1161/CIRCULATIONAHA.116.024666 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1161/CIRCULATIONAHA.116.024666
|
| Author Notes: | Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1556595875 | ||
| 003 | DE-627 | ||
| 005 | 20220813160857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170413s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCULATIONAHA.116.024666 |2 doi | |
| 035 | |a (DE-627)1556595875 | ||
| 035 | |a (DE-576)486595870 | ||
| 035 | |a (DE-599)BSZ486595870 | ||
| 035 | |a (OCoLC)1340972795 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lindner, Samuel M. |e VerfasserIn |0 (DE-588)1129883914 |0 (DE-627)884486044 |0 (DE-576)486597369 |4 aut | |
| 245 | 1 | 0 | |a Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin |b A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |c Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators |
| 264 | 1 | |c March 6, 2017 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am: 13.04.2017 | ||
| 700 | 1 | |a Hacke, Werner |d 1948- |e VerfasserIn |0 (DE-588)12021699X |0 (DE-627)080530346 |0 (DE-576)164358854 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950 |g 135(2017), 10, Seite 1001-1003 |h Online-Ressource |w (DE-627)265784670 |w (DE-600)1466401-X |w (DE-576)074891189 |x 1524-4539 |7 nnas |a Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |
| 773 | 1 | 8 | |g volume:135 |g year:2017 |g number:10 |g pages:1001-1003 |g extent:3 |a Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis |
| 856 | 4 | 0 | |u https://doi.org/10.1161/CIRCULATIONAHA.116.024666 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170413 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 12021699X |a Hacke, Werner |m 12021699X:Hacke, Werner |d 910000 |d 911100 |e 910000PH12021699X |e 911100PH12021699X |k 0/910000/ |k 1/910000/911100/ |p 9 | ||
| 999 | |a KXP-PPN1556595875 |e 2965143610 | ||
| BIB | |a Y | ||
| SER | |a newspaper | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-newspaper"},"person":[{"roleDisplay":"VerfasserIn","display":"Lindner, Samuel M.","family":"Lindner","role":"aut","given":"Samuel M."},{"role":"aut","given":"Werner","family":"Hacke","display":"Hacke, Werner","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin","title":"Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin","subtitle":"A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis"}],"note":["Gesehen am: 13.04.2017"],"recId":"1556595875","physDesc":[{"extent":"3 S."}],"id":{"eki":["1556595875"],"doi":["10.1161/CIRCULATIONAHA.116.024666"]},"language":["eng"],"relHost":[{"part":{"volume":"135","pages":"1001-1003","year":"2017","extent":"3","issue":"10","text":"135(2017), 10, Seite 1001-1003"},"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Heart Association","role":"isb"}],"origin":[{"dateIssuedKey":"1950","publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1950-","publisher":"Lippincott, Williams & Wilkins ; Ovid"}],"disp":"Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysisCirculation","pubHistory":["1.1950 -"],"type":{"bibl":"newspaper","media":"Online-Ressource"},"note":["Gesehen am 10.10.2025"],"title":[{"title_sort":"Circulation","title":"Circulation","subtitle":"an official journal of the American Heart Association"}],"recId":"265784670","language":["eng"],"id":{"zdb":["1466401-X"],"issn":["1524-4539"],"eki":["265784670"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Samuel M. Lindner, Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Günter Breithardt, Kenneth W. Mahaffey, Daniel E. Singer, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Richard C. Becker, Keith A.A. Fox, Manesh R. Patel and on behalf of the ROCKET AF Steering Committee and Investigators"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"March 6, 2017"}]} | ||
| SRT | |a LINDNERSAMTREATMENTC6201 | ||